Overall, the findings support the mechanistic role of a tumor-specific molecular axis in which PCA3 acts as dominant-negative oncogene and PRUNE2 as a tumor suppressor gene in human prostate cancer and indicate that the interplay between these genes is dysregulated early in prostate cancer. Here, PRUNE2 is linked to prostate carcinoma.